Fennec Pharmaceuticals (FENC) CFO Robert Andrade Receives 1,703 Shares

What Happened Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals (FENC), was reported on Form 4 to have acquired 1,703 shares on July 31, 2026. The shares were recorded as an award/acquisition at $0.00 (no cash paid) and represent restricted shares released to him rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-31; Filing date: 2026-08-03 (Form 4 accession 0001468308-26-000026).
• Transaction type/code: A — Grant/award or other acquisition.
• Shares acquired: 1,703 shares at $0.00 (total reported cash value $0).
• Footnote: Shares were released from restrictions from awards dated 5/16/2024 and 3/28/2025 (see F1).
• Shares owned after transaction: Not specified in the provided filing.
• No sale or market trade occurred—this is vesting/release of previously awarded restricted stock.

Context Releases of restricted shares are typically the result of vesting or meeting certain performance/time-based conditions tied to prior awards; they do not indicate a market purchase or sale by the insider. Such transactions are common as part of executive compensation and should be viewed as administrative/compensation-related rather than a direct signal of buying or selling intent.